CP-809,101 je lek koji deluje kao potentan i selektivan agonist 5-HT2C receptora.[1] On je proizveo obećavajuće rezultate u životinjskim modelima gojaznosti i psihoze, ali isto tako uzrokuje genotoksičnost, te je njegova upotreba ograničena na naučna istraživanja.[2][3]
- ↑ Strong PV, Greenwood BN, Fleshner M (May 2009). „The effects of the selective 5-HT(2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats”. Psychopharmacology 203 (4): 665–75. DOI:10.1007/s00213-008-1413-3. PMID 19037632.
- ↑ Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (February 2007). „CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity”. Neuropharmacology 52 (2): 279–90. DOI:10.1016/j.neuropharm.2006.07.024. PMID 16949622.
- ↑ Kalgutkar AS, Dalvie DK, Aubrecht J, Smith EB, Coffing SL, Cheung JR, Vage C, Lame ME, Chiang P, McClure KF, Maurer TS, Coelho RV, Soliman VF, Schildknegt K (June 2007). „Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation”. Drug Metabolism and Disposition: the Biological Fate of Chemicals 35 (6): 848–58. DOI:10.1124/dmd.106.013649. PMID 17344339.